Cat. No.: HY-13755

Sulforaphane

71 Cited Publications

Customer Review

Based on 71 publication(s) in Google Scholar

Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties.

For research use only. We do not sell to patients.

Purity: 99.01%
CAS No.: 4478-93-7
Formula: C₆H₁₁NOS₂
Molecular Weight:177.29

Storage:

-20°C, sealed storage, away from moisture and light

* The compound is unstable in solutions, freshly prepared is recommended.

Sulforaphane Chemical Structure

CAS No.: 4478-93-7

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (71)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

HDAC

Bax

Caspase-3

All HDAC Isoforms :

All Bcl-2 Family Isoforms :

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	24.52 μM Compound: SFA	Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
A-431	IC₅₀	15.76 μM Compound: SFN	Antiproliferative activity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27135370]
A-431	IC₅₀	9 μM Compound: SFN	Inhibition of EGFR-TK in human A431 cell lysate assessed as reduction in EGF stimulated kinase activity after 60 mins using biotinylated peptide substrate by ELISA Inhibition of EGFR-TK in human A431 cell lysate assessed as reduction in EGF stimulated kinase activity after 60 mins using biotinylated peptide substrate by ELISA	[PMID: 27135370]
A549	IC₅₀	>10 μM Compound: SFN	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
A549	IC₅₀	11.93 μM Compound: SFA	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
A549	IC₅₀	19.6 μM Compound: 2-RS	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25299679]
A549	IC₅₀	20.18 μM Compound: SFN	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
A549	IC₅₀	21.99 μM Compound: 77, SFN	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23685571]
AGS	IC₅₀	18.41 μM Compound: SFN	Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
ARPE-19	IC₅₀	10 μM Compound: Sulforaphane	Cytotoxicity against human ARPE-19 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human ARPE-19 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35549469]
Caco-2	IC₅₀	55.27 μM Compound: 5; SFN	Antiproliferative activity against human Caco-2 cells measured after 24 hrs by MTT assay Antiproliferative activity against human Caco-2 cells measured after 24 hrs by MTT assay	[PMID: 38142509]
Caco-2	IC₅₀	79.83 μM Compound: SF, Sulforaphane	Cytotoxicity against human Caco2 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human Caco2 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
CCRF-CEM	IC₅₀	>10 μM Compound: SFN	Antiproliferative activity against human CCRF-CEM cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human CCRF-CEM cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
DU-145	IC₅₀	10 μM Compound: 1	Antiproliferative activity against human DU145 cells assessed as viable cells after 24 hrs Antiproliferative activity against human DU145 cells assessed as viable cells after 24 hrs	[PMID: 18855447]
DU-145	IC₅₀	13.8 μM Compound: SF, Sulforaphane	Cytotoxicity against human DU145 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human DU145 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
HCC827	IC₅₀	>10 μM Compound: SFN	Antiproliferative activity against human HCC827 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HCC827 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HCT-116	IC₅₀	11.59 μM Compound: 77, SFN	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 23685571]
HCT-116	IC₅₀	36.73 μM Compound: SFA	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
HeLa	IC₅₀	>10 μM Compound: SFN	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HeLa	IC₅₀	66.09 μM Compound: SFA	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 30282324]
Hep 3B2	IC₅₀	>10 μM Compound: SFN	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HepG2	EC₅₀	1.2 μM Compound: Sulforaphane	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay	[PMID: 28126440]
HepG2	EC₅₀	4 μM Compound: sulforaphane	Induction of ARE in human HepG2 cells by luciferase assay Induction of ARE in human HepG2 cells by luciferase assay	[PMID: 16562850]
HepG2	IC₅₀	14.05 μM Compound: 77, SFN	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23685571]
HepG2	IC₅₀	20.99 μM Compound: SFN	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
HepG2	IC₅₀	24.89 μM Compound: SF, Sulforaphane	Cytotoxicity against human HepG2 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human HepG2 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
HepG2	IC₅₀	8.357 μM Compound: SFN	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HONE1 cell line	IC₅₀	19.26 μM Compound: SFN	Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
Jurkat	IC₅₀	>10 μM Compound: SFN	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
Jurkat	IC₅₀	15 μM Compound: SFN	Cytotoxicity against human Jurkat T cells assessed as decrease in cell viability after 24 hrs by flow cytometric analysis Cytotoxicity against human Jurkat T cells assessed as decrease in cell viability after 24 hrs by flow cytometric analysis	[PMID: 22200402]
Jurkat	IC₅₀	3.8 μM Compound: 1	Antiproliferative activity against human lymphoblastoid cells using annexin-V FITC and PI staining by flow cytometry Antiproliferative activity against human lymphoblastoid cells using annexin-V FITC and PI staining by flow cytometry	[PMID: 18855447]
LoVo	IC₅₀	18.52 μM Compound: SFN	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
LoVo	IC₅₀	22.9 μM Compound: SFN	Cytotoxicity against human LoVo cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human LoVo cells after 72 hrs by sulforhodamine B assay	[PMID: 28342398]
LoVo	IC₅₀	22.9 μM Compound: SFN	Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay	[PMID: 29945793]
LS174T	IC₅₀	95 μM Compound: 1	Antiproliferative activity against human LS 174T cells Antiproliferative activity against human LS 174T cells	[PMID: 18855447]
MCF7	IC₅₀	>10 μM Compound: SFN	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
MCF7	IC₅₀	17.66 μM Compound: 77, SFN	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23685571]
MCF7	IC₅₀	23.13 μM Compound: SFN	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
MDA-MB-231	IC₅₀	>10 μM Compound: SFN	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
MDA-MB-231	IC₅₀	22.18 μM Compound: SFN	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
MRC5	IC₅₀	46.58 μM Compound: 2-RS	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25299679]
NCI-H1299	IC₅₀	11.57 μM Compound: SFN	Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1299	IC₅₀	7.648 μM Compound: SFN	Antiproliferative activity against human H1299 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human H1299 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
NCI-H1650	IC₅₀	22.01 μM Compound: SFN	Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1975	IC₅₀	>10 μM Compound: SFN	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
NCI-H460	IC₅₀	21.25 μM Compound: SFN	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
OVCAR-3	IC₅₀	18.44 μM Compound: SFN	Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
PC-3	IC₅₀	32.38 μM Compound: SF, Sulforaphane	Cytotoxicity against human PC3 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human PC3 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
PC-9	IC₅₀	6.308 μM Compound: SFN	Antiproliferative activity against human PC9 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human PC9 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
Peritoneal macrophage	CC₅₀	>10 μM Compound: SFN	Cytotoxicity against mouse peritoneal macrophages assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against mouse peritoneal macrophages assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34119834]
RAW264.7	IC₅₀	400 nM Compound: sulforaphane	Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 48 hrs by Griess assay Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 48 hrs by Griess assay	[PMID: 25965897]
SGC-7901	IC₅₀	24.95 μM Compound: SFN	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
SH-SY5Y	IC₅₀	13.27 μM Compound: 77, SFN	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 23685571]
SH-SY5Y	IC₅₀	20 μM Compound: sulforaphane	Cytotoxicity against human SH-SY5Y cells after 24 hrs by Annexin V-PE-based flow cytometry Cytotoxicity against human SH-SY5Y cells after 24 hrs by Annexin V-PE-based flow cytometry	[PMID: 24140951]
SiHa	IC₅₀	9.953 μM Compound: SFN	Antiproliferative activity against human SiHa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human SiHa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
SMMC-7721	IC₅₀	7.87 μM Compound: SFA	Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK8 assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
SW480	IC₅₀	17.84 μM Compound: SFN	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
U-251	IC₅₀	22.47 μM Compound: SFN	Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
U2OS	EC₅₀	0.58 μM Compound: SFN	Activation of NRF2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay Activation of NRF2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay	[PMID: 30540174]
U2OS	EC₅₀	0.58 μM Compound: SFN	Activation of ED-tagged Nrf2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay Activation of ED-tagged Nrf2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay	[PMID: 31312409]
U2OS	EC₅₀	0.87 μM Compound: SFN	Activation of NRF2 in human U2OS cells co-expressing Keap1 (unknown origin) assessed as induction of NRF2 translocation to nucleus incubated for 6 hrs by beta-galactosidase based chemiluminescent assay Activation of NRF2 in human U2OS cells co-expressing Keap1 (unknown origin) assessed as induction of NRF2 translocation to nucleus incubated for 6 hrs by beta-galactosidase based chemiluminescent assay	[PMID: 31670201]
U-937	IC₅₀	>10 μM Compound: SFN	Antiproliferative activity against human U937 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human U937 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
Vero	IC₅₀	13.72 μM Compound: 77, SFN	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23685571]

In Vitro

Sulforaphane (0-30 μM) induces cell cycle arrest and apoptosis in a dose-dependent manner. Sulforaphane-induced cell cycle arrest is associated with an increase in the expression of cyclin A and B1^[1].
Sulforaphane (0-30 μM) inhibits the re-initiation of growth and decreases cell viability in HT29 cells, exhibiting lower toxicity towards differentiated cells^[1].
Sulforaphane (10 μM, 24 hours) pre-treatment reduces the number of apoptotic cells, decreases the expression of pro-apoptotic proteins (Bax, caspase-3, cytochrome c), and counteracts the increase in mitochondrial membrane potential induced by Doxorubicin (HY-15142A) (1 μM, 2 hours) in H9c2 cells^[2]. Sulforaphane (10 μM, 2 or 24 hours) effectively reduces ROS production and cell apoptosis in H9c2 cells induced by Doxorubicin (1 μM, 2 or 24 hours) through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

H9c2 cells
Concentration:

Sulforaphane: 10 μM; Doxorubicin: 1 μM
Incubation Time:

Sulforaphane: 2h; Doxorubicin: 2, 24h
Result:

Prevented the release of cytochrome c into the cytosol.
Prevented the translocation of Bax into the cytosol.
Attenuated the doxorubicin-induced increase in the levels of cleaved caspase-3.
Induced a significant increase in HO-1 protein expression.
Induced a significantly higher level of Nrf2 expression in the nucleus compared to the cytoplasm.

Apoptosis Analysis^[2]

Cell Line:

H9c2 cells
Concentration:

Sulforaphane: 10 μM; Doxorubicin: 1 μM
Incubation Time:

Sulforaphane: 2h; Doxorubicin: 24h
Result:

Protected the H9c2 cells against doxorubicin-induced cell death.
Increased cell viability in a dose-dependent manner.
Significantly reduced the number of apoptotic cells treated with Doxorubicin.

RT-PCR^[2]

Cell Line:

H9c2 cells
Concentration:

Sulforaphane: 10 μM; Doxorubicin: 1 μM
Incubation Time:

Sulforaphane: 2, 24h; Doxorubicin: 2, 24h
Result:

Induced heme oxygenase-1 (HO-1) mRNA expression in a dose-dependent manner.

In Vivo

Sulforaphane (13.3, 17.7, 26.6 mg/kg; Oral gavage; 5 days) is capable of inhibiting the formation of mammary tumors in female Sprague-Dawley rats following a single-dose treatment with DMBA (HY-W011845) (8 mg/mL)^[3].
Sulforaphane (13.3, 17.7, 26.6 mg/kg; Oral gavage; 5 days) can reduce the incidence, multiplicity, and weight of mammary tumors induced by DMBA (8 mg/mL) in female Sprague-Dawley rats, and delay their development^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Sprague-Dawley rat^[3]
Dosage:

Sulforaphane: 13.3, 17.7, 26.6 mg/kg; DMBA (HY-W011845): 8 mg/mL
Administration:

Oral gavage; 5 days
Result:

Prevented the occurrence of tumors in a dose-dependent manner.
Significantly reduced the incidence of tumors.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 4478-93-7
Appearance Liquid (Density: 1.17±0.1 g/cm³)
Molecular Weight 177.29
Formula C₆H₁₁NOS₂
Color Light yellow to yellow
SMILES

O=S(CCCCN=C=S)C
Structure Classification
- Others
Initial Source
- Plants
- other families
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture and light

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (71)

All RT-PCRWBIF

Sort by:

Journal Impact Factor

Nat Commun

Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors. [Abstract]

2023 Sep 18;14(1):5778. PMID: 37723178
Acta Pharm Sin B

Inhibiting autophagy enhances sulforaphane-induced apoptosis via targeting NRF2 in esophageal squamous cell carcinoma. [Abstract]

2021 May;11(5):1246-1260. PMID: 34094831
Adv Sci (Weinh)

PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma. [Abstract]

2025 May 23:e04372. PMID: 40405713
Theranostics

Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis. [Abstract]

2020 Jun 5;10(16):7319-7334. PMID: 32641994

Sulforaphane purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jun 5;10(16):7319-7334. [Abstract]

Western blot detection of Nrf2, TLR4, IRF1, iNOS, and ARG-1 levels following Sulforaphane (SFN; 10 μM or 20 μM) treatment or Nrf2 upregulation/downregulation in BMDMs co-cultured with COM-stimulated TECs. SFN treatment activates Nrf2 expression, which then downregulates the expression of TLR4, IRF1, and iNOS and upregulates the expression of ARG-1.

Sulforaphane purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jun 5;10(16):7319-7334. [Abstract]

The distribution of iNOS (green) and ARG-1 (red) in BMDMs according to immunofluorescence. Sulforaphane (SFN; 10 μM or 20 μM) decreases iNOS and increases ARG-1 levels.
J Adv Res

Tussilagone attenuated cigarette smoke-induced chronic obstructive pulmonary disease through regulating Nrf2 and NF-κB/NLRP3 inflammasome via directly targeting cysteine 434 of KEAP1. [Abstract]

2025 Jul 14:S2090-1232(25)00544-2. PMID: 40669599
J Adv Res

Aberrant activation of p53-TRIB3 axis contributes to diabetic myocardial insulin resistance and sulforaphane protection. [Abstract]

2024 Jul 26:S2090-1232(24)00307-2. PMID: 39069209
Redox Biol

Discovery of a novel chalcone-derived covalent Keap1 binder for mitigating cisplatin-induced mitochondrial dysfunction and nephrotoxicity. [Abstract]

2025 Jun 21:85:103737. PMID: 40592144
J Hazard Mater

Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function. [Abstract]

2025 Dec 2:501:140687. PMID: 41352012
Cell Death Dis

MTCH2 regulates NRF2-mediated RRM1 expression to promote melanoma proliferation and dacarbazine insensitivity. [Abstract]

2025 Apr 9;16(1):268. PMID: 40204724
Acta Pharmacol Sin

Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73. [Abstract]

2025 Jun;46(6):1722-1732. PMID: 39930134
Acta Pharmacol Sin

Sulforaphane activates anti-inflammatory microglia, modulating stress resilience associated with BDNF transcription. [Abstract]

2022 Apr;43(4):829-839. PMID: 34272506
Phytomedicine

Sulforaphane reverses the enhanced NSCLC metastasis by regulating the miR-7-5p/c-Myc/LDHA axis in the acidic tumor microenvironment. [Abstract]

2024 Oct:133:155874. PMID: 39079314
Phytomedicine

Baicalein ameliorated obesity-induced cardiac dysfunction by regulating the mitochondrial unfolded protein response through NRF2 signaling. [Abstract]

2024 Apr:126:155441. PMID: 38394729
Phytomedicine

Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer. [Abstract]

2021 Jan;80:153370. PMID: 33113504
Free Radic Biol Med

Therapeutic potential of 2-hexyl-1-decanol in Cutibacterium acnes-induced skin inflammation via modulation of oxidative and inflammatory pathways. [Abstract]

2026 Jun 3:253:596-611. PMID: 42242598
Food Chem X

Magnetic field-assisted blanching enhances sulforaphane synthesis in broccoli florets, revealed by UPLC-ESI-QTRAP-MS/MS. [Abstract]

2026 Feb 20:34:103689. PMID: 41777636
Free Radic Biol Med

Isoliquiritigenin attenuates cisplatin-induced hearing loss and ototoxicity by activating the Keap1-Nrf2-ARE pathway. [Abstract]

2025 Oct 3:241:599-616. PMID: 41046947
Free Radic Biol Med

Activation of Nrf2 modulates protective immunity against Mycobacterium tuberculosis infection in THP1-derived macrophages. [Abstract]

2022 Nov 20;193(Pt 1):177-189. PMID: 36244589
Biomed Pharmacother

Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C. [Abstract]

2021 Oct:142:111652. PMID: 34112534
Redox Rep

Sulforaphane attenuates irradiation induced testis injury in mice. [Abstract]

2023 Dec;28(1):2279818. PMID: 38052218
Antioxidants (Basel)

Effect of Media Composition and Oxygen Tension on Cellular Stress Response and Nrf2 Activation in HepG2ARE Cells. [Abstract]

025 Jan 24;14(2):137. PMID: 40002325
Antioxidants (Basel)

Activation of NRF2 Signaling Pathway Delays the Progression of Hyperuricemic Nephropathy by Reducing Oxidative Stress. [Abstract]

2023 Apr 28;12(5):1022. PMID: 37237889
J Anim Sci Biotechnol

Sulforaphane prevents LPS-induced inflammation by regulating the Nrf2-mediated autophagy pathway in goat mammary epithelial cells and a mouse model of mastitis. [Abstract]

2023 May 3;14(1):61. PMID: 37131202
Phytother Res

Sulforaphane Attenuates PM2.5-Induced Chronic Obstructive Pulmonary Disease by Modulation of Nrf2 Activating and EGFR/PI3K/AKT Signaling. [Abstract]

2026 Mar 23. PMID: 41871911
J Agric Food Chem

Bifidobacterium longum CCFM1206 Promotes the Biotransformation of Glucoraphanin to Sulforaphane That Contributes to Amelioration of Dextran-Sulfate-Sodium-Induced Colitis in Mice. [Abstract]

2023 Jan 18;71(2):1100-1112. PMID: 36604158
Transl Psychiatry

Activation of BDNF by transcription factor Nrf2 contributes to antidepressant-like actions in rodents. [Abstract]

2021 Feb 24;11(1):140. PMID: 33627628
Antioxid Redox Signal

Intervention of asprosin attenuates oxidative stress and neointima formation in vascular injury. [Abstract]

2024 Sep;41(7-9):488-504. PMID: 38814824
Food Biosci

2026 May 8;80:109051.
Cell Biol Toxicol

Protocatechuic acid relieves ferroptosis in hepatic lipotoxicity and steatosis via regulating NRF2 signaling pathway. [Abstract]

2024 Nov 26;40(1):104. PMID: 39589556
Acta Neuropathol Commun

NRF2/ARE mediated antioxidant response to glaucoma: role of glia and retinal ganglion cells. [Abstract]

2023 Oct 24;11(1):171. PMID: 37875948
Biochem Pharmacol

Nrf2 induces angiogenesis in spinal cystic echinococcosis by activating autophagy via regulating oxidative stress. [Abstract]

2024 Jun 4:226:116337. PMID: 38844265
J Ethnopharmacol

Ethyl acetate fraction of Thesium chinense Turcz. alleviates chronic obstructive pulmonary disease through inhibition of ferroptosis mediated by activating Nrf2/SLC7A11/GPX4 axis. [Abstract]

2024 Aug 31:118776. PMID: 39222758
Life Sci

Sulforaphene inhibits the progression of osteosarcoma via regulating FSTL1/NF-κB pathway. [Abstract]

2020 Dec 15;263:118485. PMID: 33017573
Nutrients

Resveratrol and FGF1 Synergistically Ameliorates Doxorubicin-Induced Cardiotoxicity via Activation of SIRT1-NRF2 Pathway. [Abstract]

2022 Sep 27;14(19):4017. PMID: 36235670
Int J Mol Sci

Sulforaphane Suppresses H2O2-Induced Oxidative Stress and Apoptosis via the Activation of AMPK/NFE2L2 Signaling Pathway in Goat Mammary Epithelial Cells. [Abstract]

2023 Jan 5;24(2):1070. PMID: 36674585
J Nutr Biochem

Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression. [Abstract]

2023 Feb:112:109226. PMID: 36435292
Front Pharmacol

Sulforaphane alleviates hepatocyte pyroptosis via activating Nrf2-HO-1 signaling during septic acute liver injury. [Abstract]

2025 Oct 16:16:1690067. PMID: 41181585
Int Immunopharmacol

Deficiency of NRF2 aggravates BLM-induced systemic sclerosis-associated fibrosis and inflammation in mice. [Abstract]

2026 Feb 15:171:116130. PMID: 41485256
Int Immunopharmacol

Targeting GCS regulates the NRF2 axis to inhibit hepatocyte endoplasmic reticulum stress-ferroptosis improving immune-mediated liver injury. [Abstract]

2025 Sep 13:165:115532. PMID: 40946670
Int Immunopharmacol

Sulforaphane modulates macrophage polarization via JAK1/STAT1 inhibition to promote tendon repair in tendinopathy. [Abstract]

2025 Aug 4:163:115302. PMID: 40763479
Am J Physiol Cell Physiol

Sulforaphane treatment mimics contractile activity-induced mitochondrial adaptations in muscle myotubes. [Abstract]

2025 Feb 1;328(2):C335-C354. PMID: 39672545
Biosci Rep

Sulforaphane enhanced muscle growth by promoting lipid oxidation through modulating key signaling pathways. [Abstract]

2024 Jun 13:BSR20240084. PMID: 38868980
Eur J Pharmacol

Sulforaphane alleviates hyperalgesia and enhances analgesic potency of morphine in rats with cancer-induced bone pain. [Abstract]

2021 Oct 15:909:174412. PMID: 34375671

Sulforaphane purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2021 Oct 15:909:174412. [Abstract]

Western blotting analysis shows that CIBP can significantly induce the protein expression of Nrf2 and HO-1 in the spinal cord and that intrathecal administration of Sulforaphane (SFN) can further promoted the protein expression of Nrf2 and HO-1 protein.

Sulforaphane purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2021 Oct 15:909:174412. [Abstract]

Immunofluorescence histochemistry confirmes that Sulforaphane (SFN) treatment further increased Nrf2 and HO-1 expression in the dorsal horn of the spinal cord of CIBP rats.
Eur J Cell Biol

dCas9-HDAC8-EGFP fusion enables epigenetic editing of breast cancer cells by H3K9 deacetylation. [Abstract]

2024 Oct 18;103(4):151463. PMID: 39437453

Sulforaphane purchased from MedChemExpress. Usage Cited in: Eur J Cell Biol. 2024 Oct 18;103(4):151463. [Abstract]

MCF-7 cells cotransfected with dCas9-HDAC8-EGFP and gRNA-B exhibited statistically significant downregulation of ESR1.Addition of Sulforaphane (2 μM, 24 h) and PCI-34051 (0.5 μM, 24 h) after cotransfection of dCas9-HDAC8-EGFP and gRNA-B in MCF-7 cells resulted in no statistically significant alteration of ESR1 expression.
Biochim Biophys Acta Mol Basis Dis

Icariin protects human nucleus pulposus cells from hydrogen peroxide-induced mitochondria-mediated apoptosis by activating nuclear factor erythroid 2-related factor 2. [Abstract]

2020 Jan 1;1866(1):165575. PMID: 31666206
J Neurochem

Spinal Nrf2 translocation may inhibit neuronal NF-κB activation and alleviate allodynia in a rat model of bone cancer pain. [Abstract]

2021 Sep;158(5):1110-1130. PMID: 34254317
Biomedicines

Characterization of a Clinically and Biologically Defined Subgroup of Patients with Autism Spectrum Disorder and Identification of a Tailored Combination Treatment. [Abstract]

2024 Apr 30;12(5):991. PMID: 38790952
Vet Res

Increased ROS levels activate AMPK-ULK1-mediated mitophagy to promote pseudorabies virus replication. [Abstract]

2025 Jul 21;56(1):156. PMID: 40691814
J Sci Food Agric

Broccoli seed extract rich in polysaccharides and glucoraphanin ameliorates DSS-induced colitis via intestinal barrier protection and gut microbiota modulation in mice. [Abstract]

2023 Mar 15;103(4):1749-1760. PMID: 36495024
Vascul Pharmacol

Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. [Abstract]

2018 Oct:109:56-71. PMID: 29908295

Sulforaphane purchased from MedChemExpress. Usage Cited in: Vascul Pharmacol. 2018 Oct:109:56-71. [Abstract]

A representative western blot analysis gel showing the reduces abundance of eNOS relative to GAPDH in tissues cultured under hyperglycaemic conditions (25 mM glucose: 25) versus either freshly isolated tissues (F, first lane on left) or tissues cultured under euglycaemic conditions (10 mM glucose: 10). The abundance of eNOS is preserved for tissues cultured in 25 mM glucose along with 1 μM Sulforaphane (25+S).
ChemMedChem

Andrographolide Derivatives Target the KEAP1/NRF2 Axis and Possess Potent Anti-SARS-CoV-2 Activity. [Abstract]

2022 Mar 4;17(5):e202100732. PMID: 35099120
Psychopharmacology (Berl)

Lipopolysaccharide-induced endotoxaemia during adolescence promotes stress vulnerability in adult mice via deregulation of nuclear factor erythroid 2-related factor 2 in the medial prefrontal cortex. [Abstract]

2023 Apr;240(4):713-724. PMID: 36847832
Ren Fail

Sulforaphane regulates AngII-induced podocyte oxidative stress injury through the Nrf2-Keap1/ho-1/ROS pathway. [Abstract]

2024 Dec;46(2):2416937. PMID: 39417305
3 Biotech

Triple regulation of oxidative-acetylation cycling pathways in COPD glucocorticoid resistance by HuaTanJiangQi capsules. [Abstract]

2025 Apr;15(4):72. PMID: 40060290
J Biochem Mol Toxicol

Blockade of Interferon-Induced Protein 35 Alleviates Cisplatin-Induced Ferroptosis in Acute Kidney Injury Through Activation of the NRF2. [Abstract]

2025 Jul;39(7):e70383. PMID: 40654249
Mol Biol Rep

mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma. [Abstract]

2022 Jan;49(1):451-461. PMID: 34731371
J Cancer Res Clin Oncol

GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway. [Abstract]

2019 Apr;145(4):861-872. PMID: 30661098
Toxicol Mech Methods

Nrf2 attenuates diquat-induced renal ferroptosis by regulating mitochondrial ferritin. [Abstract]

2026 Mar 24:1-12. PMID: 41789474
Cancer Chemother Pharmacol

Sulforaphane inhibits multiple myeloma cell-induced osteoclast differentiation and macrophage proliferation by elevating ferroportin1. [Abstract]

2024 Dec 11;95(1):3. PMID: 39661165
Sports Med Health Sci

Sulforaphane, Urolithin A, and ZLN005 induce time-dependent alterations in antioxidant capacity, mitophagy, and mitochondrial biogenesis in muscle cells. [Abstract]

2024 Apr 4;7(1):16-27. PMID: 39649792
Biochem Biophys Res Commun

Sulforaphane inhibits gastric cancer progression by regulating the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis. [Abstract]

2025 Oct 30:786:152757. PMID: 41056875
Tohoku J Exp Med

Sulforaphane Inhibits LPS-Induced Macrophage PANoptosis via TLR4/NFκB Pathway: A Potential Therapeutic Strategy for Acute Lung Injury. [Abstract]

2025 Apr 26;265(4):239-248. PMID: 39358228
Transpl Immunol

Sulforaphane alleviates hepatic ischemia-reperfusion injury through promoting the activation of Nrf-2/HO-1 signaling. [Abstract]

2021 Oct:68:101439. PMID: 34320386
bioRxiv

2025 Dec 1.
SSRN

2025 Jul 10.
Res Sq

2024 Aug 13.
Research Square Preprint

2023 May 11.
Research Square Preprint

2023 Apr 6.
Research Square Print

2022 Jul.
Research Square Preprint

2021 Jan.
Research Square Preprint

2020 Nov.

Solvent & Solubility

In Vitro:

DMSO : ≥ 62.5 mg/mL (352.53 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.6405 mL

28.2024 mL

56.4048 mL

5 mM

1.1281 mL

5.6405 mL

11.2810 mL

10 mM

0.5640 mL

2.8202 mL

5.6405 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: ≥ 50 mg/mL (282.02 mM); Clear solution

Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: ≥ 50 mg/mL (282.02 mM); Clear solution

Protocol 3

Add each solvent one by one: 30% SBE-β-CD in Saline

Solubility: 10 mg/mL (56.40 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Gamet-Payrastre L, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000 Mar 1;60(5):1426-33. [Content Brief]

[2]. Li B, et al. Sulforaphane prevents doxorubicin-induced oxidative stress and cell death in rat H9c2 cells. Int J Mol Med. 2015 Jul;36(1):53-64. [Content Brief]

[3]. Zhang Y, et al. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornylisothiocyanates. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3147-50. [Content Brief]

[4]. Chen X, et al. Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of PancreaticCancer via AMPK Dependent Signaling. ell Physiol Biochem. 2018;50(3):1201-1215. [Content Brief]

[5]. De Nicola GR, et al. Novel gram-scale production of enantiopure R-sulforaphane from Tuscan black kale seeds. Molecules. 2014 May 27;19(6):6975-86. [Content Brief]

[6]. Abdull Razis AF, et al. The natural chemopreventive phytochemical R-sulforaphane is a far more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer. Int J Cancer. 2011 Jun 15;128(12):2775-82. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.6405 mL	28.2024 mL	56.4048 mL	141.0119 mL
	5 mM	1.1281 mL	5.6405 mL	11.2810 mL	28.2024 mL
	10 mM	0.5640 mL	2.8202 mL	5.6405 mL	14.1012 mL
	15 mM	0.3760 mL	1.8802 mL	3.7603 mL	9.4008 mL
	20 mM	0.2820 mL	1.4101 mL	2.8202 mL	7.0506 mL
	25 mM	0.2256 mL	1.1281 mL	2.2562 mL	5.6405 mL
	30 mM	0.1880 mL	0.9401 mL	1.8802 mL	4.7004 mL
	40 mM	0.1410 mL	0.7051 mL	1.4101 mL	3.5253 mL
	50 mM	0.1128 mL	0.5640 mL	1.1281 mL	2.8202 mL
	60 mM	0.0940 mL	0.4700 mL	0.9401 mL	2.3502 mL
	80 mM	0.0705 mL	0.3525 mL	0.7051 mL	1.7626 mL
	100 mM	0.0564 mL	0.2820 mL	0.5640 mL	1.4101 mL

Keywords

Sulforaphane

71 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Sulforaphane

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Sulforaphane

All HDAC Isoforms

All Bcl-2 Family Isoforms

All Caspase Isoforms

Biological Activity

Chemical Information

Publications (71)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Sulforaphane

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Sulforaphane

All HDAC Isoforms

All Bcl-2 Family Isoforms

All Caspase Isoforms

Biological Activity

Chemical Information

Publications (71)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Sulforaphane Related Classifications

Cat. No.: HY-13755